Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Methylenetetrahydrofolate reductase C677T polymorphism in patients with gastric and colorectal cancer in a Korean population

Authors: Lian-Hua Cui, Min-Ho Shin, Sun-Seog Kweon, Hee Nam Kim, Hye-Rim Song, Jin-Mei Piao, Jin-Su Choi, Hyun Jeong Shim, Jun Eul Hwang, Hyeong-Rok Kim, Young-Kyu Park, Soo-Hyun Kim

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

This study was designed to investigate an association between the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and the risk of gastric and colorectal cancer in the Korean population.

Methods

We conducted a population-based large-scale case-control study involving 2,213 patients with newly diagnosed gastric cancer, 1,829 patients with newly diagnosed colorectal cancer, and 1,700 healthy controls. Genotyping was performed with peripheral blood DNA for MTHFR C677T polymorphisms. The statistical significance was estimated by logistic regression analysis.

Results

The MTHFR C677T frequencies of CC, CT, and TT genotypes were 35.2%, 47.5%, and 17.3% among stomach cancer, 34%, 50.5%, and 15.5% in colorectal cancer, and 31.8%, 50.7%, and 17.5% in the controls, respectively. The MTHFR 677TT genotype showed a weak opposite association with colorectal cancer compared to the homozygous CC genotype [adjusted age and sex odds ratio (OR) = 0.792, 95% confidence interval (CI) = 0.638-0.984, P = 0.035]. Subjects with the MTHFR 677CT showed a significantly reduced risk of gastric cancer compared whose with the 677CC genotype (age- and sex-adjusted OR = 0.810; 95% CI = 0.696-0.942, P = 0.006). We also observed no significant interactions between the MTHFR C677T polymorphism and smoking or drinking in the risk of gastric and colorectal cancer.

Conclusions

The T allele was found to provide a weak protective association with gastric cancer and colorectal cancer.
Literature
1.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57 (1): 43-66. 10.3322/canjclin.57.1.43.CrossRefPubMed
2.
Eichholzer M, Luthy J, Moser U, Fowler B: Folate and the risk of colorectal, breast and cervix cancer: the epidemiological evidence. Swiss Med Wkly. 2001, 131 (37-38): 539-549.PubMed
3.
La Vecchia C, Negri E, Pelucchi C, Franceschi S: Dietary folate and colorectal cancer. Int J Cancer. 2002, 102 (5): 545-547. 10.1002/ijc.10720.CrossRefPubMed
4.
Larsson SC, Giovannucci E, Wolk A: Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology. 2006, 131 (4): 1271-1283. 10.1053/j.gastro.2006.08.010.CrossRefPubMed
5.
Larsson SC, Hakansson N, Giovannucci E, Wolk A: Folate intake and pancreatic cancer incidence: a prospective study of Swedish women and men. J Natl Cancer Inst. 2006, 98 (6): 407-413.CrossRefPubMed
6.
Choi SW, Mason JB: Folate and carcinogenesis: an integrated scheme. J Nutr. 2000, 130 (2): 129-132.PubMed
7.
Duthie SJ: Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull. 1999, 55 (3): 578-592. 10.1258/0007142991902646.CrossRefPubMed
8.
Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996, 93 (1): 7-9.CrossRefPubMed
9.
Graziano F, Kawakami K, Ruzzo A, Watanabe G, Santini D, Pizzagalli F, Bisonni R, Mari D, Floriani I, Catalano V, et al: Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk Italian population. Int J Cancer. 2006, 118 (3): 628-632. 10.1002/ijc.21397.CrossRefPubMed
10.
Lacasana-Navarro M, Galvan-Portillo M, Chen J, Lopez-Cervantes M, Lopez-Carrillo L: Methylenetetrahydrofolate reductase 677C > T polymorphism and gastric cancer susceptibility in Mexico. Eur J Cancer. 2006, 42 (4): 528-533. 10.1016/j.ejca.2005.10.020.CrossRefPubMed
11.
Delgado-Enciso I, Martinez-Garza SG, Rojas-Martinez A, Ortiz-Lopez R, Bosques-Padilla F, Calderon-Garciduenas AL, Zarate-Gomez M, Barrera-Saldana HA: 677T mutation of the MTHFR gene in adenomas and colorectal cancer in a population sample from the Northeastern Mexico. Preliminary results. Rev Gastroenterol Mex. 2001, 66 (1): 32-37.PubMed
12.
Shannon B, Gnanasampanthan S, Beilby J, Iacopetta B: A polymorphism in the methylenetetrahydrofolate reductase gene predisposes to colorectal cancers with microsatellite instability. Gut. 2002, 50 (4): 520-524. 10.1136/gut.50.4.520.CrossRefPubMedPubMedCentral
13.
Le Marchand L, Wilkens LR, Kolonel LN, Henderson BE: The MTHFR C677T polymorphism and colorectal cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev. 2005, 14 (5): 1198-1203. 10.1158/1055-9965.EPI-04-0840.CrossRefPubMed
14.
Derwinger K, Wettergren Y, Odin E, Carlsson G, Gustavsson B: A study of the MTHFR gene polymorphism C677T in colorectal cancer. Clin Colorectal Cancer. 2009, 8 (1): 43-48. 10.3816/CCC.2009.n.007.CrossRefPubMed
15.
Kim JK, Kim S, Han JH, Kim HJ, Chong SY, Hong SP, Hwang SG, Ahn JY, Cha KY, Oh D, et al: Polymorphisms of 5,10-methylenetetrahydrofolate reductase and risk of stomach cancer in a Korean population. Anticancer Res. 2005, 25 (3B): 2249-2252.PubMed
16.
Vollset SE, Igland J, Jenab M, Fredriksen A, Meyer K, Eussen S, Gjessing HK, Ueland PM, Pera G, Sala N, et al: The association of gastric cancer risk with plasma folate, cobalamin, and methylenetetrahydrofolate reductase polymorphisms in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev. 2007, 16 (11): 2416-2424. 10.1158/1055-9965.EPI-07-0256.CrossRefPubMed
17.
Zeybek U, Yaylim I, Yilmaz H, Agachan B, Ergen A, Arikan S, Bayrak S, Isbir T: Methylenetetrahydrofolate reductase C677T polymorphism in patients with gastric and colorectal cancer. Cell Biochem Funct. 2007, 25 (4): 419-422. 10.1002/cbf.1317.CrossRefPubMed
18.
Kim HN, Lee IK, Kim YK, Tran HT, Yang DH, Lee JJ, Shin MH, Park KS, Shin MG, Choi JS, et al: Association between folate-metabolizing pathway polymorphism and non-Hodgkin lymphoma. Br J Haematol. 2008, 140 (3): 287-294. 10.1111/j.1365-2141.2007.06893.x.CrossRefPubMed
19.
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, Heuvel van den LP, et al: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature genetics. 1995, 10 (1): 111-113. 10.1038/ng0595-111.CrossRefPubMed
20.
Shen H, Newmann AS, Hu Z, Zhang Z, Xu Y, Wang L, Hu X, Guo J, Wang X, Wei Q: Methylenetetrahydrofolate reductase polymorphisms/haplotypes and risk of gastric cancer: a case-control analysis in China. Oncol Rep. 2005, 13 (2): 355-360.PubMed
21.
Shen H, Xu Y, Zheng Y, Qian Y, Yu R, Qin Y, Wang X, Spitz MR, Wei Q: Polymorphisms of 5,10-methylenetetrahydrofolate reductase and risk of gastric cancer in a Chinese population: a case-control study. Int J Cancer. 2001, 95 (5): 332-336. 10.1002/1097-0215(20010920)95:5<332::AID-IJC1058>3.0.CO;2-9.CrossRefPubMed
22.
Wang LD, Guo RF, Fan ZM, He X, Gao SS, Guo HQ, Matsuo K, Yin LM, Li JL: Association of methylenetetrahydrofolate reductase and thymidylate synthase promoter polymorphisms with genetic susceptibility to esophageal and cardia cancer in a Chinese high-risk population. Dis Esophagus. 2005, 18 (3): 177-184. 10.1111/j.1442-2050.2005.00492.x.CrossRefPubMed
23.
Galvan-Portillo MV, Cantoral A, Onate-Ocana LF, Chen J, Herrera-Goepfert R, Torres-Sanchez L, Hernandez-Ramirez RU, Palma-Coca O, Lopez-Carrillo L: Gastric cancer in relation to the intake of nutrients involved in one-carbon metabolism among MTHFR 677 TT carriers. Eur J Nutr. 2009, 48 (5): 269-76. 10.1007/s00394-009-0010-5.CrossRefPubMed
24.
Franco RF, Simoes BP, Tone LG, Gabellini SM, Zago MA, Falcao RP: The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukaemia. Br J Haematol. 2001, 115 (3): 616-618. 10.1046/j.1365-2141.2001.03140.x.CrossRefPubMed
25.
Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, Cartwright RA, Morgan G: Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA. 1999, 96 (22): 12810-12815. 10.1073/pnas.96.22.12810.CrossRefPubMedPubMedCentral
26.
Chou YC, Wu MH, Yu JC, Lee MS, Yang T, Shih HL, Wu TY, Sun CA: Genetic polymorphisms of the methylenetetrahydrofolate reductase gene, plasma folate levels and breast cancer susceptibility: a case-control study in Taiwan. Carcinogenesis. 2006, 27 (11): 2295-2300. 10.1093/carcin/bgl108.CrossRefPubMed
27.
Chen J, Giovannucci E, Kelsey K, Rimm EB, Stampfer MJ, Colditz GA, Spiegelman D, Willett WC, Hunter DJ: A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res. 1996, 56 (21): 4862-4864.PubMed
28.
Huang Y, Han S, Li Y, Mao Y, Xie Y: Different roles of MTHFR C677T and A1298C polymorphisms in colorectal adenoma and colorectal cancer: a meta-analysis. J Hum Genet. 2007, 52 (1): 73-85. 10.1007/s10038-006-0082-5.CrossRefPubMed
29.
Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Willett WC, Selhub J, Hennekens CH, Rozen R: Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res. 1997, 57 (6): 1098-1102.PubMed
30.
Jiang Q, Chen K, Ma X, Li Q, Yu W, Shu G, Yao K: Diets, polymorphisms of methylenetetrahydrofolate reductase, and the susceptibility of colon cancer and rectal cancer. Cancer Detect Prev. 2005, 29 (2): 146-154. 10.1016/j.cdp.2004.11.004.CrossRefPubMed
31.
Chen J, Giovannucci EL, Hunter DJ: MTHFR polymorphism, methyl-replete diets and the risk of colorectal carcinoma and adenoma among U.S. men and women: an example of gene-environment interactions in colorectal tumorigenesis. J Nutr. 1999, 129 (2S Suppl): 560S-564S.PubMed
32.
Hao L, Ma J, Zhu J, Stampfer MJ, Tian Y, Willett WC, Li Z: High prevalence of hyperhomocysteinemia in Chinese adults is associated with low folate, vitamin B-12, and vitamin B-6 status. J Nutr. 2007, 137 (2): 407-413.PubMed
33.
Lee JS, Kim J: Vegetable intake in Korea: data from the Korean National Health and Nutrition Examination Survey 1998, 2001 and 2005. Br J Nutr. 2010, 1-8.
34.
Suzuki T, Matsuo K, Hiraki A, Saito T, Sato S, Yatabe Y, Mitsudomi T, Hida T, Ueda R, Tajima K: Impact of one-carbon metabolism-related gene polymorphisms on risk of lung cancer in Japan: a case control study. Carcinogenesis. 2007, 28 (8): 1718-1725. 10.1093/carcin/bgm104.CrossRefPubMed
35.
Song C, Xing D, Tan W, Wei Q, Lin D: Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res. 2001, 61 (8): 3272-3275.PubMed
36.
Marugame T, Tsuji E, Inoue H, Shinomiya S, Kiyohara C, Onuma K, Hamada H, Koga H, Handa K, Hayabuchi H, et al: Methylenetetrahydrofolate reductase polymorphism and risk of colorectal adenomas. Cancer Lett. 2000, 151 (2): 181-186. 10.1016/S0304-3835(99)00412-7.CrossRefPubMed
37.
Matsuo K, Ito H, Wakai K, Hirose K, Saito T, Suzuki T, Kato T, Hirai T, Kanemitsu Y, Hamajima H, et al: One-carbon metabolism related gene polymorphisms interact with alcohol drinking to influence the risk of colorectal cancer in Japan. Carcinogenesis. 2005, 26 (12): 2164-2171. 10.1093/carcin/bgi196.CrossRefPubMed
38.
Plaschke J, Schwanebeck U, Pistorius S, Saeger HD, Schackert HK: Methylenetetrahydrofolate reductase polymorphisms and risk of sporadic and hereditary colorectal cancer with or without microsatellite instability. Cancer Lett. 2003, 191 (2): 179-185. 10.1016/S0304-3835(02)00633-X.CrossRefPubMed
39.
Miao XP, Yang S, Tan W, Zhang XM, Ye YJ, Lin DX, Wang S: Association between genetic variations in methylenetetrahydrofolate reductase and risk of colorectal cancer in a Chinese population. Zhonghua Yu Fang Yi Xue Za Zhi. 2005, 39 (6): 409-411.PubMed
40.
Guerreiro CS, Carmona B, Goncalves S, Carolino E, Fidalgo P, Brito M, Leitao CN, Cravo M: Risk of colorectal cancer associated with the C677T polymorphism in 5,10-methylenetetrahydrofolate reductase in Portuguese patients depends on the intake of methyl-donor nutrients. Am J Clin Nutr. 2008, 88 (5): 1413-1418.PubMed
41.
Stolzenberg-Solomon RZ, Qiao YL, Abnet CC, Ratnasinghe DL, Dawsey SM, Dong ZW, Taylor PR, Mark SD: Esophageal and gastric cardia cancer risk and folate- and vitamin B(12)-related polymorphisms in Linxian, China. Cancer Epidemiol Biomarkers Prev. 2003, 12 (11 Pt 1): 1222-1226.PubMed
42.
Yang CX, Matsuo K, Ito H, Shinoda M, Hatooka S, Hirose K, Wakai K, Saito T, Suzuki T, Maeda T, et al: Gene-environment interactions between alcohol drinking and the MTHFR C677T polymorphism impact on esophageal cancer risk: results of a case-control study in Japan. Carcinogenesis. 2005, 26 (7): 1285-1290. 10.1093/carcin/bgi076.CrossRefPubMed
43.
Zhang FF, Terry MB, Hou L, Chen J, Lissowska J, Yeager M, Zatonski W, Chanock S, Morabia A, Chow WH: Genetic polymorphisms in folate metabolism and the risk of stomach cancer. Cancer Epidemiol Biomarkers Prev. 2007, 16 (1): 115-121. 10.1158/1055-9965.EPI-06-0513.CrossRefPubMed
44.
Boccia S, Gianfagna F, Persiani R, La Greca A, Arzani D, Rausei S, D'Ugo D, Magistrelli P, Villari P, Van Duijn CM, et al: Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and susceptibility to gastric adenocarcinoma in an Italian population. Biomarkers. 2007, 12 (6): 635-644. 10.1080/13547500701546766.CrossRefPubMed
45.
Kim DH, Ahn YO, Lee BH, Tsuji E, Kiyohara C, Kono S: Methylenetetrahydrofolate reductase polymorphism, alcohol intake, and risks of colon and rectal cancers in Korea. Cancer Lett. 2004, 216 (2): 199-205. 10.1016/j.canlet.2004.08.014.CrossRefPubMed
Metadata
Title
Methylenetetrahydrofolate reductase C677T polymorphism in patients with gastric and colorectal cancer in a Korean population
Authors
Lian-Hua Cui
Min-Ho Shin
Sun-Seog Kweon
Hee Nam Kim
Hye-Rim Song
Jin-Mei Piao
Jin-Su Choi
Hyun Jeong Shim
Jun Eul Hwang
Hyeong-Rok Kim
Young-Kyu Park
Soo-Hyun Kim
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-236

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue

Research article

Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese

Study protocol

Rationale and design of the Exercise Intensity Trial (EXCITE): A randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancer

Research article

Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer

Research article

Moxibustion for cancer care: a systematic review and meta-analysis

Research article

Immunohistochemical analysis of oxidative stress and DNA repair proteins in normal mammary and breast cancer tissues

Case report

Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits